Although every organization has its own unique process for assessing a partnering or licensing opportunity, best practice suggests that evaluation of medical technologies should include an evaluation of product, market and legal, manufacturing, and financial issues. The final due diligence assessment report, the culmination of the evaluation process, integrates the findings of the research and development (R&D) team along with the commercial and business team’s assessment [1]. In addition, when investing in small organizations such as biotechnology companies, drug delivery companies, or specialty pharma firms, it may be necessary to conduct due diligence on the corporation itself. Specifically, the final report should not only summarize the findings of all teams but also highlight the key risks and associated probabilities that could impact the opportunity. For example, for an investment in a product in development, will there be a delay in regulatory approval? Are more studies needed to support the marketing claims? Lastly, the final due diligence report provides recommendations on whether to continue pursuit of the opportunity with a potential partner, including the potential upsides and downsides of a relationship. Ultimately, the report must satisfy the end-users of the strategic business plan—most likely senior managers responsible for investment approvals.


Final Report Medical Technology Senior Manager Financial Issue Regulatory Approval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Raymond A. Huml
    • 1
  1. 1.Quintiles Transnational CorporationDurhamUSA

Personalised recommendations